(MedPage Today) — The investigational drug daraxonrasib, now available through an early access program, demonstrated promising efficacy in previously treated pancreatic ductal adenocarcinoma (PDAC) and was associated with high-grade adverse events…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
